Navigation Links
Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
Date:6/22/2013

it of a smaller volume of subcutaneous injection compared with Lantus®.

About the EDITION Phase 3 ProgramThe EDITION program is a worldwide and comprehensive series of Phase 3 studies evaluating the efficacy and safety of new insulin U300 in broader and diverse populations of people with diabetes. The full EDITION I (basal + mealtime insulin) and EDITION II (basal Insulin + oral therapy) results are expected by the end of this year. Additionally, the following Phase 3 studies from the EDITION program are ongoing: EDITION III in insulin-naive type 2 diabetes patients , EDITION IV in type 1 diabetes patients, EDITION JP I in Japanese type 1 diabetes patients (basal + bolus insulin) and EDITION JP II in Japanese type 2 diabetes patients (basal insulin + oral therapy).

About Lantus (insulin glargine [rDNA origin] injection)Prescription Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and children (6 years and older) with type 1 diabetes for the control of high blood sugar.  It should be taken once a day at the same time each day to lower blood glucose.

Do not use Lantus to treat diabetic ketoacidosis.

Important Safety Information for LantusDo not take Lantus if you are allergic to insulin or any of the inactive ingredients in Lantus.

You must test your blood sugar levels while using insulin, such as Lantus.  Do not make any changes to your dose or type of insulin without talking to your healthcare provider.  Any change of insulin should be made cautiously and only under medical supervision.

Do NOT dilute or mix Lantus with any other insulin or solution.  It will not work as intended and you may lose blood sugar control, which could be serious.  Lantus must only be used if the solution is clear and colorless with no particles visible.  Do not share needles, insulin pens or syringes with others.The most common side effect of insulin, including Lantus
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
2. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
3. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
4. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
5. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
6. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
7. NextBio Announces Translational Medicine Partnership with Sanofi
8. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
9. Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
10. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... , , SAN DIEGO, Aug. 27 ... Company has begun a clinical trial intended to secure U.S. regulatory approval ... determine the need for a repeat prostate biopsy. , ... studies and our European commercial experience, we believe that our PROGENSA PCA3 ...
... , , , ... an 82-year old New Orleans resident with severe aortic stenosis successfully had ... as angioplasty, a far cry from the traditional open heart procedure. Patients ... now have a potential new research option available regionally only through The ...
Cached Medicine Technology:Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk 2Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk 3Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk 4Ochsner Replaces Heart Valve Without Open Heart Surgery 2
(Date:7/11/2014)... Presently, disposable medical suppliers call for the ... segment. During the past two decades, the world market ... average 12.5% per year), primarily owing to the importance ... is the largest market for disposable medical supplies in ... second position is held by Europe with a 29% ...
(Date:7/11/2014)... July 11, 2014 The Corn ... years to 2014 on the heels of fresh biofuel ... farmers to dedicate a larger share of their farmland ... specifically, the regulations required the mixing of 5.0% renewable ... production in the United States created a key export ...
(Date:7/11/2014)... Ticket Down is a reliable source ... Amphitheatre in Wheatland, CA. In the Sacramento California ... the Sleep Train Amphitheatre can do for music fans. The ... the course of its existence and can seat 18,500 fans ... Wheatland (Sacramento metro area) will host the “That’s My Kind ...
(Date:7/11/2014)... Pigments are insoluble colorants, which usually consist of ... coating, opacity, and coloring. These are water and oil ... substances such as paper, paints, plastics, and concrete. Binders ... impart color to the substance. Some examples of pigments ... , The coloring action of pigments is due to ...
(Date:7/11/2014)... York, NY (PRWEB) July 11, 2014 ... dramatic increase in men seeking cosmetic surgery and hair ... year. With such an expansive range of medical tourism ... exceptional plastic surgery costs and achieve the ... to be renowned as the top name in the ...
Breaking Medicine News(10 mins):Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 3
... a 47-year-old man who had worked for a Hindustan Lever ... who had also been exposed to toxic mercury, to the ... than 500 protestors, who said he had been slowly poisoned ... an autopsy to assess the possibility of mercury-induced damage. ...
... new study examined the connection between Baltimore City’s needle ... ,Individuals who enter treatment programs for drug addiction were ... Baltimore City needle exchange programs. ,The ... of Public Health highlights the need for treatment facilities ...
... always the result of a subtle marriage between a ... an appropriate excipient// (a neutral substance in which the ... absorbed by the body). Thus the necessary tablet, capsule ... biodegradable materials were used instead of these neutral excipients? ...
... multiple positive social outcomes,// research conducted in rural ... of the Journal of Acquired Immune Deficiency Syndromes ... appear to lead to stigmatisation or an increase ... increase in the incidence of domestic violence against ...
... transition service has been instituted by the NHS trust to ... ,‘Minding the Gap’, a document enabled by ... regular service for 16- to 18-year-olds, in Durham and Darlington. ... out to the teenagers suffering health problems across six primary ...
... Complementary //and Alternative Medicine (NCCAM) at the National Institutes ... better, especially about alternative therapies they are trying out ... ,This is the outcome of a survey conducted ... 1600 patients, and their doctors. ,It ...
Cached Medicine News:Health News:Ex-workers Ask HLL to Accept Liability for Mercury Deaths 2Health News:Drug Treatment Seekers Likely to Use Needle Exchange 2Health News:New Generation - Medicinal Products 2Health News:New Generation - Medicinal Products 3Health News:HIV Home-based Care Produces Positive Outcomes in Uganda 2Health News:HIV Home-based Care Produces Positive Outcomes in Uganda 3Health News:Elderly Patients Usually Keep Mum About Use of Alternative Medicine , Reveals Survey 2
Easy-to-use system for displaced femoral neck fractures in the low demand patient....
The APR Hip System offers a complete line of stems to precisely match patients' anatomic needs and address surgeon preferences....
Dual offset femoral stems, hip stems that provide unique and competitive features....
The P.S.L. stem is manufactured from cobalt chrome and is available with or without porous coating to give the surgeon the option of utilizing either the cementless of cemented technique at his or he...
Medicine Products: